Evidence map›Paper›PMID 41913171›Full record

ArticleBMC pediatrics2026

Neonatal sepsis: any role for procalcitonin as a diagnostic marker?

Ogechi Ezerioha, Joseph Ezeogu, Emeka Nwolisa

Abstract read
In one paragraph

Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ogechi EzeriohaDepartment of Paediatrics, Federal Teaching Hospital, Owerri, Imo State, Nigeria.
Joseph EzeoguDepartment of Paediatrics, Federal Teaching Hospital, Owerri, Imo State, Nigeria. jezeogu@yahoo.com.
Emeka NwolisaDepartment of Paediatrics, Federal Teaching Hospital, Owerri, Imo State, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn low and middle-income countries, a key driver of neonatal morbidity and mortality is neonatal sepsis. Rapid and precise diagnosis of neonatal sepsis remains a critical challenge due to limited laboratory facilities. Blood culture results, the diagnostic gold standard, are often unavailable or delayed; therefore, procalcitonin (PCT) has been considered as a potential inflammatory biomarker of bacterial infection.This study assessed the diagnostic performance of PCT in neonates with sepsis at the Federal Teaching Hospital, Owerri, Nigeria.

methodsThis cross-sectional study recruited 75 neonates aged 0–28 days with clinical suspicion of sepsis between June 2023 and February 2024. Sociodemographic and clinical data were obtained using a structured questionnaire, serum PCT levels were measured using Enzyme-linked immunosorbent assay (ELISA) and blood culture was performed as the gold standard. The primary outcome was the diagnostic accuracy of PCT for neonatal sepsis. Secondary outcomes included comparison of diagnostic performance between early-onset neonatal sepsis (EONNS) and late-onset neonatal sepsis (LONNS), and description of microbial isolates. Diagnostic indices (sensitivity, specificity, positive predictive value (PPV), negative predictive value, NPV) were calculated at different PCT thresholds. Receiver operating characteristic (ROC) curves were analysed to determine the area under the curve (AUC).

resultsOf the 75 neonates, 55 (73.3%) had culture-confirmed sepsis and 32 (58.2%) early-onset neonatal sepsis. Serum PCT levels were not normally distributed (Kolmogorov–Smirnov test, p < 0.001) and were summarized using medians and interquartile ranges. At a PCT cut-off of ≥ 2 ng/mL, sensitivity and NPV were 72.7% and 57.1% respectively while specificity and PPV remained 100% for all neonates. The AUC for PCT was significantly higher in EONNS (0.964, 95% CI: 0.910–1.000) compared to LONNS (0.788, 95% CI: 0.638–0.938). Gram-negative organisms (63.6%) were the most common isolates, mainly Escherichia coli (34.5%).

conclusionSerum procalcitonin demonstrates high specificity for culture-confirmed neonatal sepsis at a cut-off of ≥ 2.0 ng/mL in this cohort, with better diagnostic performance in early-onset disease. These findings apply to the studied population and cut-off thresholds. PCT measurement integration in Nigeria can be a priceless tool for guiding rational antibiotic therapy; particularly where rapid confirmation of sepsis is critical to improving neonatal survival outcomes.

Indexed as

Neonatal SepsisProcalcitoninBiomarkersCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansInfant, NewbornMaleNigeriaPredictive Value of TestsROC CurveSensitivity and SpecificityBiomarkersProcalcitoninBiomarkerDiagnostic accuracyEarly-onset neonatal sepsisLate-onset neonatal sepsisNeonatal sepsisProcalcitonin

Identifiers

PMID41913171
PMCPMC13154706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.